Is it time to play “small ball?”

Is it time to play “small ball?”

Get Justin's Trading Insights Every Wednesday

Is it time to play “small ball?”

If you’ve been following the markets, you’ve probably noticed a trend.

The big boys have been doing the heavy lifting.

Mega-cap leaders like Nvidia (NVDA), Google (GOOG), and Apple (AAPL) have been on a tear lately.

In many ways, they’ve carried the market.

But I think the back half of the year could look very different.

Small- and mid-cap stocks could play catch up in a major way. They could even massively outperform the indices.

I say this because both the small- and mid-cap stock ETFs have been consolidating for months. They’re storing up energy for their next major move, which I think will be to the upside.

I say this for a simple reason: Interest rates appear to have topped.

If rates held lower, that would benefit many stocks—especially more rate-sensitive groups like small- and mid-caps.

That brings me to my new Trade of the Week: Onto Innovation (ONTO).

Onto is an $11.5 billion semiconductor equipment stock. It’s much smaller than leading semi names like Nvidia, Micron Technology (MU), or Broadcom (AVGO).

We’re putting on this trade for a few reasons.

For one, ONTO isn’t just any mid-cap stock. It’s one of the strongest on the planet. It’s rallied 52% higher so far this year and 113% over the past year.

In short, it’s in a strong uptrend. And it appears to have just begun its next major leg higher. You can see what I mean below: 

Source: StockCharts (click to enlarge)

I suggest putting on a starter position in ONTO. I believe ONTO could hit $310 over the next 12 months.

Exit your position if ONTO closes below $210. That gives us a risk-reward ratio of more than 3:1 on this trade.

Action to take: Buy ONTO at current market prices.

Risk management: Exit your position if ONTO closes below $210.

Justin Spittler
Chief Trader, RiskHedge

PS: I expect to see a ton of new trade opportunities open up as market rotation continues out of mega-caps and into lesser-known names like Onto.

To stay ahead of the curve, consider joining our All-Access program. It’s a way to get everything RiskHedge publishes for the next 18 months—including my premium trading room—for a one-time flat fee… so you never miss a thing.

Go here for complete details—and a special summertime offer.

Suggested Reading...

A newly legalized investment

 

Is Pfizer (PFE) A Good Deal Right Now?




Join our community and get in on the discussion

Keep up with RiskHedge on the go.

Download the App

Scan it with your Phone


Get Justin's Trading Insights Every Wednesday

Subscribe to Trading with Justin